Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Melanoma: Update Bulletin # 1 [February 2019]

Product Code:
596201083
Publication Date:
February 2019
Format:
PDF
Price:
£1,140

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the melanoma market. KOLs gave their candid insights on the following events: Eisai/Merck & Co.’s presentation of new data from the Phase Ib/II (Study 111/KEYNOTE-146) study; Nektar Therapeutics’ presentation of new data from the PIVOT-02 Phase I/II study for bempegaldesleukin plus nivolumab (Opdivo; Bristol-Myers Squibb) in previously untreated patients with metastatic Stage IV melanoma; and OncoSec Medical announcing new data from the company's OMS-100 Phase II study for tavokinogene telseplasmid (Tavo), an interleukin-12 (IL-12) gene therapy for the treatment of MM.

Business Questions:

• How do KOLs view the current data for Eisai/Merck & Co.’s Lenvima/Keytruda combination?
• How do experts rate the chance of Lenvima/Keytruda progressing into Phase III development?
• What safety concerns do KOLs have with Lenvima/Keytruda?
• Do KOLs see Lenvima/Keytruda combination reaching the market?
• What do KOLs think of Nektar Therapeutics’ bempegaldesleukin/Opdivo combination?
• How do KOLs compare bempegaldesleukin/Opdivo to single agent checkpoint inhibitors?
• Will bempegaldesleukin/Opdivo Phase III study deliver positive results? What do KOLs say? 
• How do KOLs see the potential of OncoSec’s Tevo for melanoma?
• Which agents do KOLs say offer the best combination promise with Tavo and why?
• In which setting do experts think Tavo has the best chance of succeeding and why?





customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved